본문 바로가기 주메뉴 바로가기
  • HOME
  • Company Introduction
  • CEO Message

CEO Message

Greetings

Duck-Joo Lee, from GC Cell CEO

“We will leap into the world and become a global leader in the cell therapy products market.”

Since the inception of indigenous development of cell therapy products in 2002, GC Cell has focused on research and development, determined to deliver hope to patients and their families. As a result, in 2007, GC Cell acquired the product license of an anti-cancer immunotherapy product for liver cancer, for the first time in the world.

As a next-generation anticancer drug expressing superior therapeutic effects to conventional anticancer drugs having few side effects, GC Cell’s Immunotherapy not only kills cancer cells, but also enhances the human immune system, through which a comprehensive therapeutic effect is expected. Since its release, the company has steadily increased its earnings, mainly due to the trust of patients and physicians, and has recorded sales of more than 10 billion KRW from 2015.

In addition to sales of Immunotherapy products, GC Cell is also diversifying
its enterprise by regularizing consignment business through its excellent KGMP facilities.
It is further expediting R&D of next-generation cell therapy products such as CAR-T and
immunosuppression-avoidant T cell therapy, which will help the company to be reborn as a
market leader, leading the development of therapeutic drug market in Korea.

Furthermore, in 2017, we contracted a joint venture agreement with a Chinese company
to advance into the global market. We will leap into the world and become a global leader
in the cell therapy products market by securing competitiveness in the global market.
I would like to ask for your support and encouragement for will be a GC cell
that making a healthy life of the world.

감사합니다.

(주)녹십자셀 대표이사 이득주